Drug Resistance / Resistance Mutations / Acquired Resistance / Transmitted Resistance

TAMs (thymideine analogue mutations)
NAMs (nucleoside-associated resistance mutations)
Resistance Testing

Low Prevalence of Darunavir (Prezista) Resistance Mutations among Patients Who Experienced Treatment Failure with Other Protease Inhibitors - 10/19/07

Prevalence of Drug-resistant HIV among Newly Infected Individuals in Switzerland and Cote d'Ivoire - 10/19/07

Most Patients with Highly Drug-resistant HIV Treated with an Incompletely Suppressive Regimen Maintain Durable Immunological and Virological Responses despite Acquiring New Resistant Mutations - 10/05/07

Development of V82L/T Mutation Following Tipranavir Therapy Has Limited Effect on Susceptibility to Darunavir and Brecanavir  - 3/16/07

Entecavir Active Against HIV and Selects for Antiretroviral Resistance Mutations  - 3/06/07

Four Cases of Infection with Multidrug-resistant HIV Reported in Seattle   2/13/07

Frequent Methamphetamine Use Is Associated with Primary NNRTI Resistance 2/02/07

High Rates of Drug Resistance in Treatment-naive Individuals 2/02/07

New Improved Test for HIV Drug Resistance  1/16/07

Highlights from the 8th Annual HIV Drug Therapy Meeting in Glasgow  12/01/06

Darunavir/ritonavir plus TMC125 Shows Good Efficacy and Safety in Patients with Resistant HIV   10/03/06

HIV Persists in Aged Memory CD4 Cells during 8 Years of Effective HAART   9/29/06

The KLEAN Study: 48-week Analysis Demonstrates Non-inferiority and Rare Resistance   9/29/06

Resistance Profile After Treatment with Atazanavir-containing Regimens - 9/08/06

High Mortality Due to Multidrug-resistant Tuberculosis among HIV Positive Patients in South Africa - 8/29/06

Selection of Protease Inhibitor-Resistance Mutations During Failure of Lopinavir/ritonavir Monotherapy  - 8/22/06

Tipranavir/Ritonavir Is More Effective against Protease Inhibitor (PI)-resistant Strains than Other Ritonavir-boosted PIs   - 8/18/06

Transmission of Drug-resistant HIV Strains in Canada - 7/28/06

Prevention of Mother-to-Child Transmission of Multidrug-Resistant HIV Using T-20 Plus Tipranavir - 7/07/06

Infant-only HIV Prophylaxis Reduces Nevirapine Resistance - 3/14/06

Transmitted Drug Resistance Does Not Have a Long-term Impact on the Natural History of HIV infection or Response to First-line Therapy - 1/27/06

This Season's Flu Virus Is Resistant to 2 Standard Drugs - 1/17//06

Long-Term Virologic Follow-up of Patients Taking Tenofovir DF with Low-Level HIV-1 Viremia and the K65R Mutation In HIV-1 RT. B Chappell and others. - 12/18/05

First Report of Development of Resistance to Boosted Fosamprenavir in an ART-naïve Subject: Virologic and Clinical Outcome. P Sax and others. - 12/18/05

HIV-1 RT Mutations K70E and K65R are Not Present on the Same Viral Genome when Both Mutations are Detected in Plasma. R Lloyd and others. - 12/18/05

Selection for S68G/N/D Mutations of HIV-1 Reverse Transcriptase (RT) in Antiretroviral-Naïve Subjects Treated with Tenofovir (TDF)/Abacavir (ABC)/Lamivudine (3TC) Therapy. L Ross and others. - 12/18/05

Selection of HIV Reverse Transcriptase (RT) Thymidine Analogue Mutations (TAMS) Rather than K65R is the Preferred Route of Resistance Seen in Patients with Virologic Failure on Once-Daily (QD) Trizivir (TZV) and Tenofovir (TDF). R Elion and others. - 12/18/05

European Commission Approves Tipranavir for Treatment of HIV in Multi-drug Resistant HIV Patients - 10/28/05

Treatment Interruption as a Viable Option in Patients with Lowest CD4 Cell Count >250 Cells - 10/21/05

Lopinavir/Ritonavir-based HAART at 12 Months Has a Potent and Durable Antiretroviral Effect in Heavily Pretreated Children with Resistance to 3 Drug Classes - 10/17/05

Is There a Future for Structured Treatment Interruption in HIV Patients Failing on HAART? - 9/28/05

Structured Treatment Interruption Based on Genotypic Resistance Does Not Benefit Heavily Pretreated HIV Patients - 9/28/05

Lack of Resistance to Tenofovir at Week 48 and Impact of Baseline Resistance Mutations on Treatment Response - 8/08/05

Report on the XIV International HIV Drug Resistance Workshop: Parts 1-3 - 7/06/05

Efficacy and Tolerability of a NRTI-sparing Combination of Lopinavir/Ritonavir and Efavirenz - 6/29/05

Boehringer Ingelheim Wins FDA Approval to Market Protease Inhibitor Tipranavir (Aptivus) for Treatment of Drug-resistant HIV - 6/24/05

Multiple Drug Class-wide Resistance Is Associated with Poorer Survival after Treatment Failure - 6/22/05

Drug Resistance and Antiretroviral Drug Development - 6/24/05

Determination of Phenotypic Clinical Cutoffs for Atazanavir and Atazanavir/Ritonavir - 6/15/05

Reduced Susceptibility to Protease Inhibitors (PI) in the Absence of Primary PI Resistance-associated Mutations - 6/15/05